(Reuters) – AstraZeneca said on Wednesday a combination of cancer drugs Imfinzi and Lynparza improved progression-free survival in patients with advanced ovarian cancer, as per the results of a late-stage trial.
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Savio D’Souza)
